WASHINGTON, Feb 6, 2001 ( – The Women’s Capital Corporation (WCC), the group set up to be the manufacturer and distributor of the abortifacient morning-after pill to the United States, met Monday with the Food and Drug Administration to demand the drug’s status to be changed from prescription only to over-the-counter. The WCC has proposed allowing two studies on the drug in the US which would be submitted to the FDA after their completion in 2002, with a change in status expected shortly thereafter.

The proposals by the WCC to allow pharmacists to dispense the abortifacient drugs directly to women mirror exactly the trials currently underway in Canada, and many other countries. The similarities in the progression of MAP throughout the world is not mere coincidence. As LifeSite revealed in 1999, an international consortium is coordinating the promotion of the abortifacients with a major partner in the consortium being the United Nations. The WCC is a privately held company, organized in 1997, to bring Plan B to the U.S. and Canadian markets. Financing for Plan B has come, in large part, from U.S. foundations with interests in population control, such as the David and Lucile Packard Foundation, the Wallace Alexander Gerbode Foundation and the Compton Foundation.

See LifeSite’s report on the international consortium:

See the CNN coverage of the WCC/FDA meeting:


Commenting Guidelines

LifeSiteNews welcomes thoughtful, respectful comments that add useful information or insights. Demeaning, hostile or propagandistic comments, and streams not related to the storyline, will be removed.

LSN commenting is not for frequent personal blogging, on-going debates or theological or other disputes between commenters.

Multiple comments from one person under a story are discouraged (suggested maximum of three). Capitalized sentences or comments will be removed (Internet shouting).

LifeSiteNews gives priority to pro-life, pro-family commenters and reserves the right to edit or remove comments.

Comments under LifeSiteNews stories do not necessarily represent the views of LifeSiteNews.